nodes	percent_of_prediction	percent_of_DWPC	metapath
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—FAR2—bile duct cancer	0.0897	0.0897	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—PTGS2—bile duct cancer	0.0775	0.0775	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—ROBO2—bile duct cancer	0.0761	0.0761	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—NRAS—bile duct cancer	0.0603	0.0603	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—EGFR—bile duct cancer	0.055	0.055	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—KRAS—bile duct cancer	0.0519	0.0519	CbGpPWpGaD
Tyloxapol—LPL—Aryl Hydrocarbon Receptor—HRAS—bile duct cancer	0.0441	0.0441	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—FAR2—bile duct cancer	0.0399	0.0399	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—IDH1—bile duct cancer	0.0376	0.0376	CbGpPWpGaD
Tyloxapol—LPL—Transcriptional regulation of white adipocyte differentiation—TGFB1—bile duct cancer	0.0371	0.0371	CbGpPWpGaD
Tyloxapol—LPL—Alzheimers Disease—TP53—bile duct cancer	0.0299	0.0299	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—TGFB1—bile duct cancer	0.0244	0.0244	CbGpPWpGaD
Tyloxapol—LPL—Disease—RNF43—bile duct cancer	0.0233	0.0233	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—SMAD4—bile duct cancer	0.0212	0.0212	CbGpPWpGaD
Tyloxapol—LPL—Disease—IDH1—bile duct cancer	0.02	0.02	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—IDH2—bile duct cancer	0.0195	0.0195	CbGpPWpGaD
Tyloxapol—LPL—Adipogenesis—IL6—bile duct cancer	0.0184	0.0184	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—IDH1—bile duct cancer	0.0168	0.0168	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—RNF43—bile duct cancer	0.0163	0.0163	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MET—bile duct cancer	0.0162	0.0162	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP2—bile duct cancer	0.0135	0.0135	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—ERBB2—bile duct cancer	0.0119	0.0119	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—SLC5A5—bile duct cancer	0.0111	0.0111	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFBR2—bile duct cancer	0.0106	0.0106	CbGpPWpGaD
Tyloxapol—LPL—Metabolism of lipids and lipoproteins—PTGS2—bile duct cancer	0.0104	0.0104	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—MMP9—bile duct cancer	0.0102	0.0102	CbGpPWpGaD
Tyloxapol—LPL—Disease—SMAD4—bile duct cancer	0.0101	0.0101	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—NRAS—bile duct cancer	0.00903	0.00903	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—GNAS—bile duct cancer	0.0086	0.0086	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—TGFB1—bile duct cancer	0.00839	0.00839	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—EGFR—bile duct cancer	0.00823	0.00823	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—KRAS—bile duct cancer	0.00777	0.00777	CbGpPWpGaD
Tyloxapol—LPL—Disease—NOS2—bile duct cancer	0.0075	0.0075	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFBR2—bile duct cancer	0.00745	0.00745	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—GNAS—bile duct cancer	0.00719	0.00719	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—SMAD4—bile duct cancer	0.00705	0.00705	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—HRAS—bile duct cancer	0.00661	0.00661	CbGpPWpGaD
Tyloxapol—LPL—Developmental Biology—IL6—bile duct cancer	0.00632	0.00632	CbGpPWpGaD
Tyloxapol—LPL—Disease—ERBB2—bile duct cancer	0.00564	0.00564	CbGpPWpGaD
Tyloxapol—LPL—Disease—PTGS2—bile duct cancer	0.00551	0.00551	CbGpPWpGaD
Tyloxapol—LPL—Metabolism—PTGS2—bile duct cancer	0.00462	0.00462	CbGpPWpGaD
Tyloxapol—LPL—Disease—NRAS—bile duct cancer	0.00429	0.00429	CbGpPWpGaD
Tyloxapol—LPL—Disease—TGFB1—bile duct cancer	0.00399	0.00399	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—ERBB2—bile duct cancer	0.00395	0.00395	CbGpPWpGaD
Tyloxapol—LPL—Disease—EGFR—bile duct cancer	0.00391	0.00391	CbGpPWpGaD
Tyloxapol—LPL—Disease—KRAS—bile duct cancer	0.00369	0.00369	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—MMP9—bile duct cancer	0.00339	0.00339	CbGpPWpGaD
Tyloxapol—LPL—Disease—HRAS—bile duct cancer	0.00314	0.00314	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—NRAS—bile duct cancer	0.003	0.003	CbGpPWpGaD
Tyloxapol—LPL—Disease—IL6—bile duct cancer	0.003	0.003	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TGFB1—bile duct cancer	0.00279	0.00279	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—EGFR—bile duct cancer	0.00274	0.00274	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—KRAS—bile duct cancer	0.00258	0.00258	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—TP53—bile duct cancer	0.0023	0.0023	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—HRAS—bile duct cancer	0.0022	0.0022	CbGpPWpGaD
Tyloxapol—LPL—Signaling Pathways—IL6—bile duct cancer	0.0021	0.0021	CbGpPWpGaD
